ERBB2 and metastatic colorectal cancer: We anticipate the results of the ongoing MOUNTAINEER-03 phase III trial, which is evaluating tucatinib combined with trastuzumab and chemotherapy as first-line treatment for HER2-positive metastatic colorectal cancer (28).